First Heartland Consultants’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-4,844
Closed -$222K – 349
2022
Q1
$222K Sell
4,844
-486
-9% -$23.2K 0.03% 317
2021
Q4
$326K Sell
5,330
-398
-7% -$27.5K 0.01% 260
2021
Q3
$428K Sell
5,728
-200
-3% -$16.8K 0.07% 225
2021
Q2
$548K Buy
5,928
+190
+3% +$16.2K 0.08% 201
2021
Q1
$509K Buy
+5,738
New +$569K 0.08% 199

Other funds holding ARKG

First Heartland Consultants's ARKG Position: Q2 2022 in Review

First Heartland Consultants sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 4,844 shares — an estimated $222K sold.

First Heartland Consultants first reported a position in ARKG in Q1 2021 and held it in 5 quarters. The position peaked at $548K in Q2 2021. 334 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

  • First Heartland Consultants reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
  • First Heartland Consultants sold 4,844 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $222K.
  • First Heartland Consultants first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 5 quarters.
  • First Heartland Consultants's ARK Genomic Revolution ETF position peaked at $548K in Q2 2021.
  • 334 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on First Heartland Consultants's 13F filing for Q2 2022, filed 12 Jul 2022.